Skip navigation

Action Plan Strategies for Long Term Success ● Navigate Evolving Regulations ● Educate Stakeholders ● Accelerate Market Access

January 22-23, 2020
  • Washington, DC

As more biosimilar products continue to be added to the FDA pipeline, it is critical that bio/pharmaceutical companies develop strategies to streamline and increase uptake of these innovative products.

CBI’s 15th Annual Biosimilars Summit features insights from industry experts, including biosimilar and bio/pharmaceutical manufacturers, payers, providers and patient advocates, into tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry, including biosimilar development and adoption.

Join CBI and explore the current U.S. climate for biosimilars, evaluate competition and benchmark with industry peers. Brainstorm strategies to increase market access through commercialization, enhance collaboration between stakeholders and address the changing landscape of the biosimilars market.

Hear Expert Insights On:

  • Critical updates on the latest FDA biosimilar guidance and proposed government rulings including rebate removal that will affect the biosimilar market
  • Payer insights on leveraging interchangeability data,
    formulary placement and reimbursement
  • Biosimilar uptake and product switching policies across
    various care models
  • Internal efforts to cut development and
    commercialization costs
  • Stakeholder engagement and commercial potential through successful product marketing and branding
  • Best practices for education of HCPs, patients and
    patient advocates
  • Patient and advocacy organizations role in
    cost and access issues
  • Management of the medical benefit and its relationship to reimbursement
  • And more!

Q&A with Chrys Kokino:

Chrys Kokino, Mylan’s Global Commercial Head for Biologics and Insulins, recently gave a keynote address at CBI’s 14th Annual Biosimilars Summit on identifying best practices for biosimilar market adoption. Here, we capture some of his key thoughts on the biosimilars market today.

Download the Q&A (PDF)

Biosimilar News:

Biologic medicines that represent approximately $100 billion in sales are expected to be off patent by the year 2020. That represents a substantial opportunity for biosimilar medicines to create savings for the U.S.
health care system. The question is, will we be able to act sooner
rather than later to make a difference for patients today?

STAT News (March 20, 2019)

Insurers must be willing to take a short-term financial loss to get long-term savings from adopting biosimilars, outgoing Food and Drug Administration Commissioner Scott Gottlieb said Tuesday.

Modern Healthcare (March 19, 2019)

By 2023, 18 of the top 20 branded drugs will face generic or biosimilar competition, and the biosimilar market is expected to be three times larger than today’s, according to the report. A notable example is AbbVie’s blockbuster Humira, which will lose its U.S. patent in 2023.

MM&M (January 29, 2019)

Previous Attendee Acclaim:

CBI put together a very well-balanced, informative program. The attendees and speakers were very energetic and demonstrated their passion for biosimilars through very thoughtful and engaging discussion across stakeholder groups.

Executive Director, Biologics & Biosimilars Collective Intelligence Consortium

Efficiently run conference with insightful presenters
that led to engaging conversations.

Director of Pharmacy, Employers Health

CBI’s Biosimilars Summit is a great way to learn the latest in market acceptance and uptake for biosimilars and the challenges the biosimilars industry is facing to
help develop this emerging product area.

FDA Counsel, Arent Fox

This conference has a great line-up of speakers and the conference atmosphere enabled excellent discussion.

Global Head, Pricing, Market Access, & Policy, Biosimilars, Merck

’Rookie' or ‘Veteran’ in the biosimilars space – this conference allows you to gain some key learnings! It’s the great intimate professional setting to learn from esteemed colleagues, including potential competitors without risk!

Marketing, Merck

Eye opening conference for every new person in biosimilars.

Regulatory Affairs, Amgen

15th Annual Biosimilars Summit

Action Plan Strategies for Long Term Success ● Navigate Evolving Regulations ● Educate Stakeholders ● Accelerate Market Access

As more biosimilar products continue to be added to the FDA pipeline, it is critical that bio/pharmaceutical companies develop strategies to streamline and increase uptake of these innovative products.

CBI’s 15th Annual Biosimilars Summit features insights from industry experts, including biosimilar and bio/pharmaceutical manufacturers, payers, providers and patient advocates, into tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry, including biosimilar development and adoption.

Join CBI and explore the current U.S. climate for biosimilars, evaluate competition and benchmark with industry peers. Brainstorm strategies to increase market access through commercialization, enhance collaboration between stakeholders and address the changing landscape of the biosimilars market.

Hear Expert Insights On:

  • Critical updates on the latest FDA biosimilar guidance and proposed government rulings including rebate removal that will affect the biosimilar market
  • Payer insights on leveraging interchangeability data,
    formulary placement and reimbursement
  • Biosimilar uptake and product switching policies across
    various care models
  • Internal efforts to cut development and
    commercialization costs
  • Stakeholder engagement and commercial potential through successful product marketing and branding
  • Best practices for education of HCPs, patients and
    patient advocates
  • Patient and advocacy organizations role in
    cost and access issues
  • Management of the medical benefit and its relationship to reimbursement
  • And more!

Q&A with Chrys Kokino:

Chrys Kokino, Mylan’s Global Commercial Head for Biologics and Insulins, recently gave a keynote address at CBI’s 14th Annual Biosimilars Summit on identifying best practices for biosimilar market adoption. Here, we capture some of his key thoughts on the biosimilars market today.

Download the Q&A (PDF)

Biosimilar News:

Biologic medicines that represent approximately $100 billion in sales are expected to be off patent by the year 2020. That represents a substantial opportunity for biosimilar medicines to create savings for the U.S.
health care system. The question is, will we be able to act sooner
rather than later to make a difference for patients today?

STAT News (March 20, 2019)

Insurers must be willing to take a short-term financial loss to get long-term savings from adopting biosimilars, outgoing Food and Drug Administration Commissioner Scott Gottlieb said Tuesday.

Modern Healthcare (March 19, 2019)

By 2023, 18 of the top 20 branded drugs will face generic or biosimilar competition, and the biosimilar market is expected to be three times larger than today’s, according to the report. A notable example is AbbVie’s blockbuster Humira, which will lose its U.S. patent in 2023.

MM&M (January 29, 2019)

Previous Attendee Acclaim:

CBI put together a very well-balanced, informative program. The attendees and speakers were very energetic and demonstrated their passion for biosimilars through very thoughtful and engaging discussion across stakeholder groups.

Executive Director, Biologics & Biosimilars Collective Intelligence Consortium

Efficiently run conference with insightful presenters
that led to engaging conversations.

Director of Pharmacy, Employers Health

CBI’s Biosimilars Summit is a great way to learn the latest in market acceptance and uptake for biosimilars and the challenges the biosimilars industry is facing to
help develop this emerging product area.

FDA Counsel, Arent Fox

This conference has a great line-up of speakers and the conference atmosphere enabled excellent discussion.

Global Head, Pricing, Market Access, & Policy, Biosimilars, Merck

’Rookie' or ‘Veteran’ in the biosimilars space – this conference allows you to gain some key learnings! It’s the great intimate professional setting to learn from esteemed colleagues, including potential competitors without risk!

Marketing, Merck

Eye opening conference for every new person in biosimilars.

Regulatory Affairs, Amgen